Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Key Points

• To evaluate the efficacy of nivolumab and ipilimumab in patients with melanoma and untreated brain metastases.
• Utilized a randomized trial design (CheckMate 204, NCT02320058).
• Evaluated effects on patients with melanoma and untreated brain metastases.
• Measured both intracranial and extracranial responses.
• Nivolumab plus ipilimumab showed clinically meaningful intracranial efficacy.
• Intracranial activity correlated with extracranial responses.